Healthcare entity
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Novartis, the most common co-covered peer. Each story carries 4 original sources on average, compared with 2.3 for the broader beat in this window.
Last mentioned: Mar 10, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Of the tracked stories, 1 of 1 also mention Novartis, the most common co-covered peer. Each story carries 4 original sources on average, compared with 2.3 for the broader beat in this window. Their average consequence score of 7 runs above the beat's 5.9 for that window. TLX591 appears in 1 tracked Healthcare story from March 10, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 39 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering TLX591. Shared-story counts are live from our verified record — not editorial picks.
Interim Analysis
Expected interim efficacy data from the larger global patient cohort.
Primary Objectives Met
Announcement that Part 1 successfully validated safety and dosimetry profiles.
Enrollment Milestone
Completion of patient enrollment for the Part 1 SELECT lead-in phase.
Study Initiation
Launch of the ProstACT Global Phase 3 study for mCRPC.
Telix Pharmaceuticals has successfully met the primary objectives for Part 1 of its global Phase 3 ProstACT study, validating the safety and dosimetry of its lead therapeutic candidate, TLX591. This milestone de-risks the antibody-based radiopharmaceutical program and clears the path for the trial's continued expansion in metastatic castration-resistant prostate cancer.
Source: sydneysun.com · wallstreet-online.de
TLX591 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
